Year All2026202520242023202220212020201920182017201620152014 Apr 14, 2025 Soleno Therapeutics Announces VYKAT(TM) XR Launch Mar 26, 2025 Soleno Therapeutics Announces U.S. FDA Approval of VYKAT™ XR to Treat Hyperphagia in Prader-Willi Syndrome Feb 27, 2025 Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results Jan 29, 2025 Soleno Therapeutics to Participate in Upcoming February Investor Conferences Dec 17, 2024 Soleno Therapeutics Enters Into $200 Million Debt Financing with Oxford Finance LLC Nov 27, 2024 Soleno Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference Nov 26, 2024 Soleno Therapeutics Announces FDA Extension of Review Period for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome Nov 14, 2024 Soleno Therapeutics Announces Oral Presentations featuring Diazoxide Choline Extended-Release (DCCR) Tablets in Prader-Willi Syndrome at ESPE 2024 Nov 06, 2024 Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results Oct 28, 2024 Soleno Therapeutics to Participate in Upcoming November Investor Conferences
Mar 26, 2025 Soleno Therapeutics Announces U.S. FDA Approval of VYKAT™ XR to Treat Hyperphagia in Prader-Willi Syndrome
Feb 27, 2025 Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results
Nov 26, 2024 Soleno Therapeutics Announces FDA Extension of Review Period for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome
Nov 14, 2024 Soleno Therapeutics Announces Oral Presentations featuring Diazoxide Choline Extended-Release (DCCR) Tablets in Prader-Willi Syndrome at ESPE 2024
Nov 06, 2024 Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results